The limited data also necessitated many additional assumptions, including assumptions that can have a big impact on the estimated survival benefits like effect of maintenance after platinum-doublet chemotherapy, as well as assumptions about comparative safety and health utility data for ROS1+ NSCLC patients, which were assumed to be generalizable from the proxy ALK+ NSCLC population. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.